Robin Carson
Overview
Explore the profile of Robin Carson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani S, Chari A, et al.
Leukemia
. 2025 Feb;
PMID: 40016302
In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed...
2.
Perrot A, Facon T, Plesner T, Usmani S, Kumar S, Bahlis N, et al.
Eur J Haematol
. 2025 Feb;
PMID: 39952901
Objectives: This final post hoc analysis evaluated patient-reported outcomes from the Phase 3 MAIA study of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) after median 64.5-month follow-up...
3.
Usmani S, Facon T, Hungria V, Bahlis N, Venner C, Braunstein M, et al.
Nat Med
. 2025 Feb;
PMID: 39948407
No abstract available.
4.
Usmani S, Facon T, Hungria V, Bahlis N, Venner C, Braunstein M, et al.
Nat Med
. 2025 Feb;
PMID: 39910273
Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide...
5.
Moreau P, Facon T, Usmani S, Bahlis N, Raje N, Plesner T, et al.
Leukemia
. 2025 Jan;
39(3):710-719.
PMID: 39815052
In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival (PFS) and overall survival versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible...
6.
Yong K, Einsele H, Schecter J, Roccia T, Deraedt W, Lendvai N, et al.
Eur J Cancer
. 2024 Dec;
215:115157.
PMID: 39673835
Background: The introduction of proteasome inhibitors (PIs) and lenalidomide as treatment for newly diagnosed multiple myeloma (MM) has led to an increased population of lenalidomide-refractory patients. Limited data are available...
7.
Landgren C, Chari A, Cohen Y, Spencer A, Voorhees P, Sandhu I, et al.
Blood
. 2024 Dec;
PMID: 39652826
Early intervention of smoldering multiple myeloma (SMM) may delay progression to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS study (NCT02316106). In total, 123 patients...
8.
Dimopoulos M, Voorhees P, Schjesvold F, Cohen Y, Hungria V, Sandhu I, et al.
N Engl J Med
. 2024 Dec;
PMID: 39652675
Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor...
9.
Rajkumar S, Mateos M, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, et al.
Blood Cancer J
. 2024 Dec;
14(1):215.
PMID: 39638995
This study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma (SMM). This retrospective, observational study leveraged data from the Flatiron Health database. Eligible...
10.
Badros A, Badros A, Foster L, Anderson Jr L, Chaulagain C, Pettijohn E, et al.
Blood
. 2024 Sep;
145(3):300-310.
PMID: 39331724
No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the primary results of the phase 3 AURIGA study...